Felix Tarbangdo
Overview
Explore the profile of Felix Tarbangdo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dama E, Porgho S, Ake Y, Yameogo I, Gampini S, Adjami A, et al.
Front Public Health
. 2024 Aug;
12:1384382.
PMID: 39139671
Introduction: In 2017, the Ministry of Health and Public Hygiene (MoH) of Burkina Faso designed and piloted a specimen transport system using the national courier services (La Poste BF) in...
2.
Aksnes B, Walldorf J, Nkwenkeu S, Zoma R, Mirza I, Tarbangdo F, et al.
Vaccine
. 2021 Sep;
39(43):6370-6377.
PMID: 34579975
Background: In March 2017, Burkina Faso introduced meningococcal serogroup A conjugate vaccine (MACV) into the Expanded Programme on Immunization. MACV is administered to children aged 15-18 months, concomitantly with the...
3.
Walker J, Soeters H, Novak R, Diallo A, Vuong J, Bicaba B, et al.
J Infect Dis
. 2021 Sep;
224(12 Suppl 2):S218-S227.
PMID: 34469549
Since 2010, the introduction of an effective serogroup A meningococcal conjugate vaccine has led to the near-elimination of invasive Neisseria meningitidis serogroup A disease in Africa's meningitis belt. However, a...
4.
Mbaeyi S, Sampo E, Dinanibe K, Yameogo I, Congo-Ouedraogo M, Tamboura M, et al.
Lancet Infect Dis
. 2020 Jul;
20(12):1418-1425.
PMID: 32653071
Background: In the first 2 years after a nationwide mass vaccination campaign of 1-29-year-olds with a meningococcal serogroup A conjugate vaccine (MenAfriVac) in Burkina Faso, carriage and disease due to...
5.
Nkwenkeu S, Jalloh M, Walldorf J, Zoma R, Tarbangdo F, Fall S, et al.
BMC Public Health
. 2020 Feb;
20(1):254.
PMID: 32075630
Background: Meningococcal serogroup A conjugate vaccine (MACV) was introduced in 2017 into the routine childhood immunization schedule (at 15-18 months of age) in Burkina Faso to help reduce meningococcal meningitis...
6.
Mbaeyi S, Lingani C, Diallo A, Bicaba B, Ouedraogo-Traore R, Acyl M, et al.
J Infect Dis
. 2019 Nov;
220(220 Suppl 4):S155-S164.
PMID: 31671451
Background: The MenAfriNet consortium was established in 2014 to support implementation of case-based meningitis surveillance in 5 countries in the meningitis belt of sub-Saharan Africa: Burkina Faso, Chad, Mali, Niger,...
7.
Zoma R, Walldorf J, Tarbangdo F, Patel J, Diallo A, Nkwenkeu S, et al.
J Infect Dis
. 2019 Nov;
220(220 Suppl 4):S233-S243.
PMID: 31671442
Background: After successful meningococcal serogroup A conjugate vaccine (MACV) campaigns since 2010, Burkina Faso introduced MACV in March 2017 into the routine Expanded Programme for Immunization schedule at age 15-18...
8.
Soeters H, Diallo A, Bicaba B, Kadade G, Dembele A, Acyl M, et al.
J Infect Dis
. 2019 Nov;
220(220 Suppl 4):S165-S174.
PMID: 31671441
Background: The MenAfriNet Consortium supports strategic implementation of case-based meningitis surveillance in key high-risk countries of the African meningitis belt: Burkina Faso, Chad, Mali, Niger, and Togo. We describe bacterial...
9.
Tartof S, Cohn A, Tarbangdo F, Djingarey M, Messonnier N, Clark T, et al.
PLoS One
. 2017 Dec;
12(12):e0190188.
PMID: 29261797
[This corrects the article DOI: 10.1371/journal.pone.0063605.].
10.
Tartof S, Cohn A, Tarbangdo F, Djingarey M, Messonnier N, Clark T, et al.
PLoS One
. 2013 May;
8(5):e63605.
PMID: 23671685
Objective: The optimal long-term vaccination strategies to provide population-level protection against serogroup A Neisseria meningitidis (MenA) are unknown. We developed an age-structured mathematical model of MenA transmission, colonization, and disease...